ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2015
Immune biomarkers of anti-EGFR monoclonal antibody therapy.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Pooled it
- Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.The oncologist · 2023Review
- Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2023Review
- STAT3 pathway in cancers: Past, present, and future.MedComm · 2022Review
- EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.Cancers · 2022Article
- Application of lipid nanovesicle drug delivery system in cancer immunotherapy.Journal of nanobiotechnology · 2022Review
- Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing.Scientific reports · 2021Article
- Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing.Translational oncology · 2021Article
- The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody CetuximabFrontiers in immunology · 2021Review
- The Current Landscape of Antibody-based Therapies in Solid Malignancies.Theranostics · 2021Review
- Aberrant up-regulation of iNOS/NO system is correlated with an increased abundance of Foxp3Inflammopharmacology · 2019Article
- Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.Head & neck · 2019Article
- Predictive Value of [Molecular imaging and biology · 2019Article
- Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors.Frontiers in oncology · 2019Review
- Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.Neoplasia (New York, N.Y.) · 2018Article
- Expressional analysis of disease-relevant signalling-pathways in primary tumours and metastasis of head and neck cancers.Scientific reports · 2018Article
- Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Journal of clinical pharmacology · 2018Review
- Article
- Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.European journal of cancer (Oxford, England : 1990) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The tumor antigen (TA)-targeted monoclonal antibodies (mAb) cetuximab and panitumumab target the human epidermal growth factor receptor and have been integrated into treatment regimens for advanced squamous cell carcinoma of the head and neck (SCCHN). The therapeutic efficacy of these mAbs has been found to be enhanced when combined with radiotherapy and chemotherapy. However, clinical trials indicate that these findings are limited to fewer than 20% of treated patients. Therefore, identifying patients who are likely to benefit from these agents is crucial to improving therapeutic strategies. Interestingly, it has been noted that TA-targeted mAbs mediate their effects by contributing to cell-mediated cytotoxicity in addition to inhibition of downstream signaling pathways. Here, we describe the potential immunogenic mechanisms underlying these clinical findings, their role in the varied clinical response and identify the putative biomarkers of antitumor activity. We review potential immunological biomarkers that affect mAb therapy in SCCHN patients, the implications of these findings and how they translate to the clinical scenario, which are critical to improving patient selection and ultimately outcomes for patients undergoing therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.